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While remarkable gains in health have been achieved since 
the mid-20th century, they have been unequally distributed, 
and mortality and morbidity burdens in some regions remain 
enormous. Of the almost 10 million children under 5 years 
of age who died in 2006, only 100 000 died in industrialised 
countries, while 4.8 million died in sub-Saharan Africa.1 
In deciding whether to finance an intervention to improve 
population health, policy makers commonly weigh the 
expected population health gains against the costs of 
the intervention. Most vaccinations included in national 
immunisation schedules, such as measles vaccination, are both 
effective in preventing ill health and relatively inexpensive.2 
Newer vaccinations, such as those with pneumococcal 
conjugate vaccine (PCV) or rotavirus vaccine, can effectively 
prevent child mortality and morbidity but are expensive 
relative to the vaccinations currently included in national 
immunisation schedules. Policy makers may therefore decide 
that – at current prices – the comparison of health gains 
with costs does not justify the free public provision of these 
vaccinations. We argue that in addition to the health benefits 
of vaccinations, their effects on education and income3 and 
their benefits for unvaccinated community members can be 
considerable and should therefore be included in calculations 
to establish the value of vaccinations.
Most economic evaluations of vaccinations focus heavily on 
the benefits of avoided health care costs (Table I). While it is 
theoretically possible to take productivity gains into account 
in economic evaluation (Table II), traditionally, evaluations of 
vaccinations have either not considered such gains or have 
only included one particular type of gain: the value of the 
time that parents would have spent caring for a sick child 
had a disease episode not been averted by vaccination (care-
related productivity gains, Table I).4 Such a narrow perspective 
may lead to substantial underestimates of the value of some 
vaccinations. It neglects lifetime productivity gains because 
a vaccination prevents diseases that can cause cognitive 
impairment, lead to physical handicap, or reduce school 
attendance (outcome-related productivity gains, Table I). Cost-
benefit analyses (CBAs) in developing countries find return 
on investment in vaccinations (due to improved cognitive 
development and worker productivity)5 of similar magnitude 
to the return on investment in education.6 
A narrow focus on care-related productivity gains further 
excludes increases in productivity due to changes in 
behaviour in response to vaccination effects (behaviour-related 
productivity gains, Table I). Many vaccinations significantly 
reduce child mortality from infectious diseases. As child 
mortality declines, parents realise that they can give birth 
to fewer children to attain their desired minimum number 
of offspring.7 Reduced fertilty leads to a decreasing ratio 
of economically dependent people in a population, which 
increases the labour force per capita and savings. Savings, in 
turn, can be invested in the physical and human capital needed 
for economic growth. As average family size decreases, parents 
are likely to invest more in the education and health of each 
child, leading to improved productivity in adulthood.
Most economic evaluations of vaccinations also do not 
consider the value of externalities in the wider community, 
i.e. the effect of a child’s vaccination on non-vaccinated 
community members. Such community externalities (Table I) 
include reductions in infection rates in unvaccinated people 
because vaccinations reduce the probability that a healthy 
individual will encounter an infectious person (up to the point 
of herd immunity, where sufficient numbers of people are 
vaccinated such that infection of one individual will not result 
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in an epidemic). They also include decreased rates of antibiotic 
resistance because less antibiotics are used when more children 
are protected by vaccination against bacterial infections.
Applying the broad perspective to 
value of vaccination in South Africa
Taking a broad perspective may be especially important in 
evaluating vaccinations in South Africa (Table I). From 1976 to 
2006, the proportion of the South African population younger 
than 15 years of age fell from 42% to 32%8 as  fertility declined,9 
in part the result of HIV-related infertility and fetal loss.10 At 
the same time, the fraction of working-age adults increased 
(while the fraction of people aged 65 years and above remained 
approximately constant).8  When the ratio of children and 
elderly per working-age adult decreases, a country has an 
opportunity to develop economically because increased savings 
lead to greater investment in physical and human capital.7 
Health is an important form of human capital, including 
health attained through vaccinations. South Africa has 
made great strides in increasing coverage of basic childhood 
immunisation. The South African Demographic and Health Survey 
reported coverage with routine vaccines in children 12 - 23 
months of age ranging from 62% for measles vaccination to 
81% for bacille Calmette-Guérin (BCG) vaccination in 2003.11 
Vaccinations have contributed significantly to South Africa’s 
decline in child mortality. From 1975 to 1990, under-5 mortality 
declined by almost half, from 110 to 60 deaths per 1 000 live 
births.9 However, this trend has been reversed recently, largely 
because of the HIV epidemic.12 The under-5 mortality rate 
in South Africa was 69 per 1 000 live births in 200611 and is 
therefore not on target to achieving the UN’s Millennium 
Development Goal of reducing under-5 mortality by two-thirds 
between 1990 and 2015.  
Many interventions that could reduce child mortality in 
South Africa – such as improved access to safe water and 
sanitation, improved childhood nutrition, or poverty reduction 
– require large infrastructure investment or sustained changes 
in social policy. In this situation, the recent decision by the 
South African Department of Health to add PCV and rotavirus 
vaccinations to the national immunisation schedule, despite 
their comparatively high prices,13 is noteworthy and may serve 
as an example for other countries to follow.
Table I. Types of benefits in economic evaluations of vaccinations
Perspective Type of benefit      Definition
   Health gains      Reduction in morbidity and 
          mortality through vaccination
   Health care cost savings     Savings of medical expenditures  
          because vaccination prevents illness episodes
   Care-related productivity gains    Savings of parents’ productive time  
          because vaccination avoids the need for  
          taking care of a sick child
   Outcome-related productivity gains    Increased productivity because vaccination  
          improves cognition, physical strength, and  
          school attainment
   Behaviour-related productivity gains    Benefits accruing because vaccination improves 
          child health and survival and thereby changes  
          household behaviour
   Community externalities     Benefits accruing because vaccination improves 
          outcomes in unvaccinated community  
          members
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Table II. Types of economic evaluations
Term            Definition
Cost-effectiveness analysis (CEA)          Comparison of the health effectiveness of an intervention (measured in a common unit, e.g. 
quality-adjusted life-years) to its costs (measured in money units)
            Productivity gains and externalities can be taken into account as cost reductions
Cost-benefit analysis (CBA)            Comparison of the benefits and costs of an intervention (both measured in money units)
             Productivity gains and externalities can be taken into account as benefit increases (or cost 
reductions)
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Pneumococcal diseases are a major cause of childhood 
mortality and morbidity in South Africa.14 PCV is effective 
in preventing pneumococcal diseases, including pneumonia, 
meningitis and otitis media. (While we describe productivity 
gains and externalities using the example of PCV vaccination, 
a similar case of substantial vaccination benefits can be made 
for the rotavirus vaccine.)  Because HIV-infected children 
are at significantly higher risk of acquiring pneumococcal 
disease than uninfected children, PCV will prevent larger 
numbers of pneumococcal infections and deaths in HIV-
infected children, even though they are less likely to develop 
a protective immune reaction in response to PCV than HIV-
uninfected children.15 A large randomised controlled trial in 
South Africa found that PCV prevented 267 and 2 573 cases 
of pneumococcal pneumonia per 100 000 person-years in 
HIV-uninfected and HIV-infected children, respectively.14 PCV 
vaccination is therefore an appropriate intervention to mitigate 
the negative effect of HIV on child mortality. In addition to its 
health benefits, PCV coverage may lead to behaviour-related 
productivity gains, if the mortality reduction due to vaccination 
accelerates South Africa’s current fertility decline.
PCV is further likely to lead to considerable outcome-
related productivity gains. First, episodes of pneumococcal 
pneumonia will keep children, especially those who are 
HIV-infected, out of school for substantial periods of time, 
preventing cognitive development and learning.16 Second, 
survivors of pneumococcal meningitis frequently suffer from 
severe cognitive and neurological sequelae; a study in The 
Gambia found that 58% of children who had survived a bout 
of pneumococcal meningitis ’had clinical sequelae; half of 
them had major disabilities preventing normal adaptation to 
social life’, such as mental retardation, hearing loss, motor 
abnormalities and seizures.17 Third, pneumococcal otitis media 
can impair cognitive development; a study in the USA found 
that time spent with middle ear effusion during the first 3 
years of life was significantly associated with lower scores 
on tests of cognitive ability, speech and language, and lower 
school performance at age 7 years.18 Fourth, pneumococcal 
otitis media leads to hearing loss in a substantial proportion 
of affected children.19 While hearing-impaired children in 
developed countries receive specialised support necessary to 
attain educational levels on par with non-deaf children, such 
systems are lacking in many developing countries.20  
Moreover, PCV coverage is likely to benefit unvaccinated 
community members. It decreases the rate of occurrence of 
antibiotic-resistant pneumococcal infections,21 avoiding the 
health costs of untreatable disease and the health care costs of 
using more expensive second-line antibiotics. As pneumococcal 
disease can cause substantial morbidity and mortality in 
the elderly and in the HIV-infected middle-aged, childhood 
PCV vaccination is likely to lead to substantial reduction in 
pneumococcal disease burden in population groups that will 
not routinely receive the vaccination. A study in the USA taking 
such herd effects into account found large benefits from the 
externality,22 but most other studies of PCV value have ignored 
them.23  Herd protection against pneumococcal disease may be 
especially important in South Africa, where a large proportion 
of the adult population is HIV-positive and therefore 
vulnerable to severe recurrent pneumococcal infections.
Conclusions
South Africa has proven its commitment to ensuring that 
children receive effective vaccines, attaining high national 
vaccination coverage levels. In 2006 the country pledged $20 
million to the International Finance Facility for Immunization 
(IFFIm), the major source of finance for the GAVI Alliance’s 
effort to extend coverage with new and under-used vaccines 
to low-income countries.24 More recently, South Africa decided 
to include PCV and rotavirus vaccinations in its national 
immunisation schedule.25 It is highly likely that coverage of 
children with the two vaccines will not only reduce child 
morbidity and mortality, but will also lead to significant 
productivity gains, contributing to South Africa’s economic 
development, and benefit unvaccinated South Africans. The 
precise size of the contributions of these productivity gains and 
externalities to health and wealth in South Africa are unknown. 
Adding the two vaccinations to the national immunisation 
schedule offers an excellent opportunity to measure these 
effects, and evaluation studies should complement the 
vaccination roll-out. As the evidence grows, we expect the 
estimates of the value of many vaccinations to increase 
significantly, ensuring that policy makers have the necessary 
information to make optimal choices on vaccination provision.
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